Human coronavirus 229E

CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

Retrieved on: 
Tuesday, December 6, 2022

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.

Key Points: 
  • The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.
  • Application of this funding will now be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the Coronavirus X potential of VBIs technology.
  • We have long recognized the public health value that multivalent vaccines capable of anticipating new variants and coronavirus strains could provide.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

Middle East Respiratory Syndrome (MERS) Drug Pipeline Market Insights Report 2022: 12+ Companies and 12+ Pipeline Drugs in the Pipeline Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022

The "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.

Key Points: 
  • The "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.
  • The assessment part of the report embraces, in depth Middle East Respiratory Syndrome commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Middle East Respiratory Syndrome R&D.
  • The companies which have their Middle East Respiratory Syndrome drug candidates in the most advanced stage, i.e.

Applied Optoelectronics, Inc. Launches Quantum Bandwidth™

Retrieved on: 
Friday, September 16, 2022

The newly announced Quantum BandwidthTM products include:

Key Points: 
  • The newly announced Quantum BandwidthTM products include:
    Quantum BandwidthTM Cable Plant Signal Generator (CPSG).
  • Quantum BandwidthTM Broadband Digital Access (BDA) shelf module.
  • Quantum BandwidthTM is a family of products that together enable service providers to cost-effectively deliver scalable, high-speed data connectivity to their customers.
  • Applied Optoelectronics Inc. (AOI) is a leading developer and manufacturer of advanced optical products, including components, modules and equipment.

CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine

Retrieved on: 
Tuesday, July 5, 2022

CEPI will provide seed funding of up to US $2.5 million to Codiak BioSciencesa clinical-stage biopharmaceutical company based in Cambridge, MA, USAto continue the advancement of vaccine candidates from its pan Betacoronavirus program through preclinical studies.

Key Points: 
  • CEPI will provide seed funding of up to US $2.5 million to Codiak BioSciencesa clinical-stage biopharmaceutical company based in Cambridge, MA, USAto continue the advancement of vaccine candidates from its pan Betacoronavirus program through preclinical studies.
  • Dr Richard Hatchett, CEO of CEPI said: The COVID pandemic is not over and the R&D job is not done.
  • Initiating the development of broadly protective coronavirus vaccines should be an integral part of the worlds long-term strategy out of this pandemic.
  • CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics.

CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

Retrieved on: 
Wednesday, April 6, 2022

Details on the Phase 3 UB-612-305 clinical trial can be found at clinicaltrials.gov using Identifier NCT05293665 .

Key Points: 
  • Details on the Phase 3 UB-612-305 clinical trial can be found at clinicaltrials.gov using Identifier NCT05293665 .
  • Approximately 1,000 healthy adults will take part in the Vaxxinity-sponsored multi-center international trial, with the first subjects already dosed in the US.
  • If successful, this trial may enable global authorizations, including in high income countries and LMICs.
  • This CEPI-supported trial will generate additional evidence to inform booster strategies in people previously vaccinated with vaccines distributed through COVAX, including against variants of concern.

Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR)

Retrieved on: 
Monday, March 21, 2022

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today presented data evaluating the antiviral activity of PRTX007, a novel, small molecule toll-like receptor 7 (TLR7) specific agonist, at the International Conference on Antiviral Research (ICAR).

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today presented data evaluating the antiviral activity of PRTX007, a novel, small molecule toll-like receptor 7 (TLR7) specific agonist, at the International Conference on Antiviral Research (ICAR).
  • PRTX007 demonstrated antiviral activity in both cell and murine models against RSV, as well as in cell models against SARS-CoV-2 and seven other RNA viruses.
  • These findings demonstrate broad-spectrum antiviral activity and suitability of PRTX007 as a clinical candidate to treat acute viral infections and for stockpiling for pandemic preparedness.
  • Primmune is also evaluating the safety and tolerability of PRTX007 in an ongoing first-in-human clinical trial.

Mawer Mutual Funds Now Available Through RBC Direct Investing

Retrieved on: 
Wednesday, March 9, 2022

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Mawer Investment Management Ltd. (Mawer) announced today that units in all eligible Series A Mawer mutual funds are now available for investors to purchase through RBC Direct Investing , the brokerage division of the Royal Bank of Canada.

Key Points: 
  • CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Mawer Investment Management Ltd. (Mawer) announced today that units in all eligible Series A Mawer mutual funds are now available for investors to purchase through RBC Direct Investing , the brokerage division of the Royal Bank of Canada.
  • Mawer Mutual Funds (Mawer Funds) are designed to meet a wide variety of investment needs and risk profiles.
  • The management expense ratios (MERs) on the Mawer Funds are also amongst the lowest for actively managed mutual funds in Canada.1
    We are very pleased to announce the availability of thirteen Mawer Mutual Funds on the RBC Direct Investing platform, says Craig Senyk, Mawer President and Vice Chair.
  • The Mawer Mutual Funds are managed by Mawer Investment Management Ltd. Mutual fund securities are not covered by the Canada Deposit Insurance Corporation or by any other government deposit insurer.

Bermuda Committed to Cooperation and Compliance in Global Tax Standards

Retrieved on: 
Monday, February 28, 2022

Following the European Unions (EU) Code of Conduct Group including Bermuda on the state of play document (Annex II), the Bermuda Business Development Agency (BDA) and its valued partners, notes that Bermuda is committed to cooperation and compliance in relation to global tax standards.

Key Points: 
  • Following the European Unions (EU) Code of Conduct Group including Bermuda on the state of play document (Annex II), the Bermuda Business Development Agency (BDA) and its valued partners, notes that Bermuda is committed to cooperation and compliance in relation to global tax standards.
  • David Hart, BDA CEO, said, Bermuda prides itself on being a blue-chip financial services jurisdiction, particularly around global (re)insurance, and is committed to cooperation and compliance in global tax standards.
  • As a result, Bermuda is an active contributor to the EU, and is a global leader in regulation and technical compliance.
  • Bermuda has been consistently recognised for its transparency and adherence to global tax reporting, AML/ATF, and economic substance compliance requirements.

Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses

Retrieved on: 
Tuesday, December 21, 2021

In vivo data with multiple animal challenge models that are widely used to evaluate COVID-19 treatments support AR-701's broad efficacy.

Key Points: 
  • In vivo data with multiple animal challenge models that are widely used to evaluate COVID-19 treatments support AR-701's broad efficacy.
  • AR-701 is a cocktail of two fully human immunoglobulin G1 (IgG1) mAbs discovered from screening the antibody secreting B-cells of convalescent SARS-CoV-2 infected (COVID-19) patients.
  • The two mAbs complement and enhance each other in a synergistic fashion, creating a potent first-in-class cocktail.
  • Aridis Pharmaceuticals, Inc. discovers and developsnovel anti-infective therapies to treat life-threatening infections,including anti-infectives to be used as add-on treatments to standard-of-care antibiotics.

CEPI Partners with Affinivax to Develop a Novel COVID-19 Vaccine to Target Variants

Retrieved on: 
Monday, December 13, 2021

CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax, Inc. (Affinivax) today announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.

Key Points: 
  • CEPI, the Coalition for Epidemic Preparedness Innovations, and Affinivax, Inc. (Affinivax) today announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.
  • CEPIs investment in Affinivax will fund vaccine candidate design and selection, manufacturing process development and preclinical testing against specific SARS-CoV-2 variants.
  • CEPI will evaluate the potential for further investment in the development of this vaccine candidate based on the data derived from this initial partnership with Affinivax.
  • During the current pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale and access.